-- Intercell Rises on Start of Phase II Study for TB Vaccine
-- B y   Z o e   S c h n e e w e i s s
-- 2012-01-11T17:01:03Z
-- http://www.bloomberg.com/news/2012-01-11/intercell-rises-on-start-of-clinical-study-for-tb-vaccine-1-.html
Intercell AG (ICLL)  rose the most in more
than 2 weeks in Vienna trading after announcing that the start
of the first clinical Phase II study to develop vaccines against
Tuberculosis.  Intercell shares climbed 2.1 percent to 1.899 euros at the
5:30 p.m. close in the Austrian capital, its biggest increase
since Dec. 27.  The Austrian company is collaborating with Statens Serum
Institut on the vaccine, Intercell said in a statement today.  To contact the editor responsible for this story:
Zoe Schneeweiss at 
 zschneeweiss@bloomberg.net  